http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 25 Oct 2026 04:35:20 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Xencor+reports+Phase+1+dose+data+for+kidney+cancer+drug+XmAb819/27229263.html <p>Xencor, Inc. (NASDAQ: XNCR) presented updated Phase 1 results for XmAb819, a bispecific T-cell engaging antibody targeting ENPP3 x CD3, in patients with advanced clear cell renal cell carcinoma (ccRCC). The data were presented at the European Society for Medical Oncology Congress 2026 in Madrid, Spain.</p> <p>As of a September 1, 2026 data cut, the Phase 1 study enrolled 119 patients across 11 intravenous dose levels. Three dose levels — 100 mcg/kg, 200 mcg/kg and 400 mcg/kg — were selected for expansion evaluation. Patients in the expansion cohorts had received a median of three prior lines of therapy, with all having http://www.streetinsider.com/FDA/Xencor+reports+Phase+1+dose+data+for+kidney+cancer+drug+XmAb819/27229263.html Sun, 25 Oct 2026 04:35:20 -0400 XNCR http://www.streetinsider.com/Press+Releases/Xencor+Presents+Phase+1+Dose+Selection+Data+for+XmAb819%2C+a+Potential+First-in-Class+ENPP3+x+CD3+Bispecific+T-Cell+Engager%2C+in+Development+for+Patients+With+Advanced+Clear+Cell+Renal+Cell+Carcinoma+and/27229262.html <p class="bwalignc"> -- 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate -- </p><p class="bwalignc"> -- Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC patient subgroups in 1H2027 -- </p><p class="bwalignc"> -- Xencor plans global randomized study of monotherapy XmAb819 compared to tivozanib in a post PD-(L)1 and VEGFR TKI ccRCC patient population -- </p><p class="bwalignc"> -- Management to host webcast Monday, October 26 at 7:00 a.m. ET / 4:00 a.m. PT -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the http://www.streetinsider.com/Press+Releases/Xencor+Presents+Phase+1+Dose+Selection+Data+for+XmAb819%2C+a+Potential+First-in-Class+ENPP3+x+CD3+Bispecific+T-Cell+Engager%2C+in+Development+for+Patients+With+Advanced+Clear+Cell+Renal+Cell+Carcinoma+and/27229262.html Sun, 25 Oct 2026 04:35:00 -0400 XNCR http://www.streetinsider.com/Business+Wire/Xencor+Presents+Phase+1+Dose+Selection+Data+for+XmAb819%2C+a+Potential+First-in-Class+ENPP3+x+CD3+Bispecific+T-Cell+Engager%2C+in+Development+for+Patients+With+Advanced+Clear+Cell+Renal+Cell+Carcinoma+and/27229262.html <p class="bwalignc"> -- 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate -- </p><p class="bwalignc"> -- Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC patient subgroups in 1H2027 -- </p><p class="bwalignc"> -- Xencor plans global randomized study of monotherapy XmAb819 compared to tivozanib in a post PD-(L)1 and VEGFR TKI ccRCC patient population -- </p><p class="bwalignc"> -- Management to host webcast Monday, October 26 at 7:00 a.m. ET / 4:00 a.m. PT -- </p> <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the http://www.streetinsider.com/Business+Wire/Xencor+Presents+Phase+1+Dose+Selection+Data+for+XmAb819%2C+a+Potential+First-in-Class+ENPP3+x+CD3+Bispecific+T-Cell+Engager%2C+in+Development+for+Patients+With+Advanced+Clear+Cell+Renal+Cell+Carcinoma+and/27229262.html Sun, 25 Oct 2026 04:35:00 -0400 XNCR http://www.streetinsider.com/FDA/Xencor+to+webcast+Phase+1+results+of+XmAb819+in+kidney+cancer/27200498.html <p>Xencor, Inc. (NASDAQ: XNCR) announced it will host a webcast on October 26 at 7:00 a.m. EDT to discuss Phase 1 study results of XmAb819, an ENPP3 x CD3 bispecific antibody in development for patients with advanced clear cell renal cell carcinoma (ccRCC).</p> <p>The results will first be presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on October 25. The presentation will be delivered by Sumanta Pal, M.D., professor and vice chair of academic affairs at City of Hope Comprehensive Cancer Center.</p> <p>According to the company's press release, Xencor is planning to http://www.streetinsider.com/FDA/Xencor+to+webcast+Phase+1+results+of+XmAb819+in+kidney+cancer/27200498.html Mon, 19 Oct 2026 07:01:14 -0400 XNCR http://www.streetinsider.com/Press+Releases/Xencor+to+Host+Webcast+to+Discuss+Results+From+the+Phase+1+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/27200494.html <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma (ccRCC). </p><p> The live webcast of the conference call may be accessed through <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxencor-xmab819-results-esmo2026-webcast.open-exchange.net%2F&amp;esheet=54624259&amp;newsitemid=20261019387869&amp;lan=en-US&amp;anchor=this+link&amp;index=1&amp;md5=ea87f0f5c0ae63dc9b1a2d62c0ec4705" shape="rect">this link</a> and through “Events &amp; Presentations” in the Investors section of the Company’s website, located at http://www.streetinsider.com/Press+Releases/Xencor+to+Host+Webcast+to+Discuss+Results+From+the+Phase+1+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/27200494.html Mon, 19 Oct 2026 07:01:00 -0400 XNCR http://www.streetinsider.com/Business+Wire/Xencor+to+Host+Webcast+to+Discuss+Results+From+the+Phase+1+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/27200494.html <p> PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell carcinoma (ccRCC). </p><p> The live webcast of the conference call may be accessed through <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fxencor-xmab819-results-esmo2026-webcast.open-exchange.net%2F&amp;esheet=54624259&amp;newsitemid=20261019387869&amp;lan=en-US&amp;anchor=this+link&amp;index=1&amp;md5=ea87f0f5c0ae63dc9b1a2d62c0ec4705" shape="rect">this link</a> and through “Events &amp; Presentations” in the Investors section of the Company’s website, located at http://www.streetinsider.com/Business+Wire/Xencor+to+Host+Webcast+to+Discuss+Results+From+the+Phase+1+Study+of+XmAb819+in+Advanced+Clear+Cell+Renal+Cell+Carcinoma/27200494.html Mon, 19 Oct 2026 07:01:00 -0400 XNCR http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Analyst+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html <p>RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'.</p><p>The analyst comments "ESMO is likely the biggest event for MRK/MRNA for the rest of this year. On INTerpath-001, expectations are elevated after the study hit at the first interim look in August. KOLs are split on where the ph3 HR lands, ranging from 0.5 (on par with ph2) to 0.7 (reflecting typical maturation drift), but we think investors will need to see a 0.5-0.59 HR to believe INT has a real shot in other tumor types (NSCLC, RCC, bladder). We think the risk/reward feels somewhat http://www.streetinsider.com/Hot+Comments/RBC%3A+%27ESMO+is+likely+the+biggest+event+for+MRKMRNA+for+the+rest+of+this+year%27/27196832.html Fri, 16 Oct 2026 10:51:45 -0400 CATX MRK MRNA XNCR http://www.streetinsider.com/Investing/Raymond+James+Updates+Healthcare+Top+Picks+for+October/27135679.html <p>Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">UnitedHealth</span></span> Group to replace <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Relay</span></span> Therapeutics, Tyra Biosciences, and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Oscar Health</span></span>.</p> <p>1. <strong><span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Xencor Inc</span></span>. (XNCR)</strong></p> <p>Raymond James added Xencor to its top picks list, replacing Relay Therapeutics. The firm anticipates significant interest in Xencor&amp;#39;s dataset at ESMO at the end of October. Raymond James sees near-term upside to shares on a positive readout and clear path to pivotal development for http://www.streetinsider.com/Investing/Raymond+James+Updates+Healthcare+Top+Picks+for+October/27135679.html Thu, 01 Oct 2026 16:00:03 -0400 CLYM UNH XNCR http://www.streetinsider.com/Investing/Raymond+James+Updates+Healthcare+Top+Picks+for+October/27135679.html <p>Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">UnitedHealth</span></span> Group to replace <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Relay</span></span> Therapeutics, Tyra Biosciences, and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Oscar Health</span></span>.</p> <p>1. <strong><span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Xencor Inc</span></span>. (XNCR)</strong></p> <p>Raymond James added Xencor to its top picks list, replacing Relay Therapeutics. The firm anticipates significant interest in Xencor&amp;#39;s dataset at ESMO at the end of October. Raymond James sees near-term upside to shares on a positive readout and clear path to pivotal development for http://www.streetinsider.com/Investing/Raymond+James+Updates+Healthcare+Top+Picks+for+October/27135679.html Thu, 01 Oct 2026 16:00:03 -0400 CLYM UNH XNCR http://www.streetinsider.com/Investing/Raymond+James+Updates+Healthcare+Top+Picks+for+October/27135679.html <p>Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">UnitedHealth</span></span> Group to replace <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Relay</span></span> Therapeutics, Tyra Biosciences, and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Oscar Health</span></span>.</p> <p>1. <strong><span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Xencor Inc</span></span>. (XNCR)</strong></p> <p>Raymond James added Xencor to its top picks list, replacing Relay Therapeutics. The firm anticipates significant interest in Xencor&amp;#39;s dataset at ESMO at the end of October. Raymond James sees near-term upside to shares on a positive readout and clear path to pivotal development for http://www.streetinsider.com/Investing/Raymond+James+Updates+Healthcare+Top+Picks+for+October/27135679.html Thu, 01 Oct 2026 16:00:03 -0400 CLYM UNH XNCR http://www.streetinsider.com/New+Coverage/Wells+Fargo+Assumes+Xencor%2C+Inc.+%28XNCR%29+at+Overweight/27124854.html <p>Wells Fargo analyst Derek Archila assumes coverage on Xencor, Inc. (NASDAQ: XNCR) with a Overweight rating and a price target of $55.00.</p> <p>For an analyst ratings summary and ratings history on Xencor, Inc. <a href="http://www.streetinsider.com/rating_history.php?q=XNCR">click here</a>. For more ratings news on Xencor, Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=XNCR&amp;type=analyst">click here</a>.</p> <p>Shares of Xencor, Inc. closed at $25.00 yesterday.</p> http://www.streetinsider.com/New+Coverage/Wells+Fargo+Assumes+Xencor%2C+Inc.+%28XNCR%29+at+Overweight/27124854.html Wed, 30 Sep 2026 06:23:33 -0400 XNCR http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2429+at+Truist+Securities/27109988.html (Updated - September 28, 2026 9:09 AM EDT) <p>Truist Securities analyst Gregory Renza raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $29.00 (from $27.00) while maintaining a Buy rating.</p><p>The analyst commented: "We see XmAb819's upcoming ESMO update (Oct.25) as a key near-term re-rating event for XNCR, with initial activity, our KOL work and recent discussion with mgmt supporting a potentially favorable setup. We view maintenance of ~25% ORR with >6-mo mPFS and a manageable CRS profile as sufficient to support ph.III advancement. We assign a 70% probability to our Best/Good scenarios and +11.5% PoS-weighted upside. Our ~$800M XmAb819 peak http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2429+at+Truist+Securities/27109988.html Mon, 28 Sep 2026 09:09:43 -0400 XNCR http://www.streetinsider.com/Analyst+Comments/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2429+at+Truist+Securities/27109988.html (Updated - September 28, 2026 9:09 AM EDT) <p>Truist Securities analyst Gregory Renza raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $29.00 (from $27.00) while maintaining a Buy rating.</p><p>The analyst commented: "We see XmAb819's upcoming ESMO update (Oct.25) as a key near-term re-rating event for XNCR, with initial activity, our KOL work and recent discussion with mgmt supporting a potentially favorable setup. We view maintenance of ~25% ORR with >6-mo mPFS and a manageable CRS profile as sufficient to support ph.III advancement. We assign a 70% probability to our Best/Good scenarios and +11.5% PoS-weighted upside. Our ~$800M XmAb819 peak http://www.streetinsider.com/Analyst+Comments/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2429+at+Truist+Securities/27109988.html Mon, 28 Sep 2026 09:09:43 -0400 XNCR http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2435+at+Barclays/27050224.html Barclays analyst Etzer Darout raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $35.00 (from $27.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2435+at+Barclays/27050224.html Fri, 11 Sep 2026 05:30:12 -0400 XNCR http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2421+at+JPMorgan/27022501.html JPMorgan analyst Brian Cheng raised the price target on Xencor, Inc. (NASDAQ: XNCR) to $21.00 (from $14.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Xencor%2C+Inc.+%28XNCR%29+PT+Raised+to+%2421+at+JPMorgan/27022501.html Thu, 03 Sep 2026 08:32:22 -0400 XNCR http://www.streetinsider.com/Press+Releases/Xencor+to+Present+at+the+2026+Cantor+Global+Healthcare+Conference/27018771.html <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.</p><p>A live webcast of the presentation will be available under “Events &amp; Presentations” in the Investors section of Xencor’s website located at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.xencor.com&amp;esheet=54598158&amp;newsitemid=20260902523892&amp;lan=en-US&amp;anchor=www.xencor.com&amp;index=1&amp;md5=b584dc3831e4f2d59482305c168660da" shape="rect">www.xencor.com</a>. A replay of the event will be available for at least 30 days following the presentation.</p><p><strong>About Xencor</strong></p><p>Xencor is a clinical-stage biopharmaceutical company developing http://www.streetinsider.com/Press+Releases/Xencor+to+Present+at+the+2026+Cantor+Global+Healthcare+Conference/27018771.html Wed, 02 Sep 2026 16:01:00 -0400 XNCR http://www.streetinsider.com/Business+Wire/Xencor+to+Present+at+the+2026+Cantor+Global+Healthcare+Conference/27018771.html <p> PASADENA, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.</p><p>A live webcast of the presentation will be available under “Events &amp; Presentations” in the Investors section of Xencor’s website located at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.xencor.com&amp;esheet=54598158&amp;newsitemid=20260902523892&amp;lan=en-US&amp;anchor=www.xencor.com&amp;index=1&amp;md5=b584dc3831e4f2d59482305c168660da" shape="rect">www.xencor.com</a>. A replay of the event will be available for at least 30 days following the presentation.</p><p><strong>About Xencor</strong></p><p>Xencor is a clinical-stage biopharmaceutical company developing http://www.streetinsider.com/Business+Wire/Xencor+to+Present+at+the+2026+Cantor+Global+Healthcare+Conference/27018771.html Wed, 02 Sep 2026 16:01:00 -0400 XNCR http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html <p>Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.</p><p>The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+on+Biotechnology%3A+%27Look+for+Biotech+to+Outperform+through+YE%3A26%27/27010029.html Tue, 01 Sep 2026 09:07:24 -0400 ALNY ARVN ARWR CAPR CRSP CTMX GENB GLUE IBRX LEGN MESO MRNA STRO XNCR